If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 81 - 90 of 289

Combination Post-Transplant Consolidation Therapy with Isatuximab, Lenalidomide, Dexamethasone (IsaRD) in Multiple Myeloma Patients with Persistent Marrow Minimal Residual Disease (Elimination of MRD After Transplant; E-MAT)

The purpose of this study is to test the safety and effectiveness of the new study drug combination of Isatuximab, Lenalidomide, and Dexamethasone for the treatment of multiple myeloma in patients with Persistent Marrow Minimal Residual Disease.
Protocol No
IIT-MOHAN-E-MAT

BLAST MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML

What are the good and bad effects of adding the study drug pembrolizumab to the usual treatment for patients with chronic myelogenous leukemia (CML)? The usual approach is defined as care most people get for CML and includes treatment with tyrosine kinase inhibitors (TKIs).
Protocol No
ECOG-EA9171

A Multicenter, Open-Label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-Cell Malignancies

This project is being done to test the safety of zilovertamab vedotin when given alone or
with nemtabrutinib, and to see how well zilovertamab vedotin works when given alone or with nemtabrutinib to treat B-cell cancers.
Protocol No
MERCK-MK2140-006-CLL-NHL